Table 2.
Person-days and crude incidence rates of diabetes among initiators of angiotensin receptor blockers
| Losartan | Valsartan | Irbesartan | Candesartan | Telmisartan | Olmesartan | |
|---|---|---|---|---|---|---|
| Exposed person-days |
160,956,721 |
252,964,999 |
115,243,240 |
44,349,122 |
46,800,437 |
26,163,756 |
| Mean follow-up days |
1263.57 |
1378.66 |
1425.48 |
1124.76 |
1336.51 |
992.22 |
| Mean treatment duration (days) |
312.03 |
349.32 |
379.50 |
344.67 |
329.76 |
271.00 |
| Mean daily dosage (DDD) |
0.36 |
0.39 |
0.39 |
0.41 |
0.42 |
0.37 |
| Number of newly diagnosed diabetes |
16,227 |
25,849 |
11,436 |
4,371 |
4,666 |
2,809 |
| Crude incidence rate per 1,000,000 person-days (95% CI) | 100.82 (99.26-102.37) | 102.18 (100.94-103.43) | 99.23 (97.41-101.05) | 98.56 (95.64-101.48) | 99.70 (96.84-102.56) | 107.36 (103.39-111.33) |